Inclusion Criteria for Adults:
- Healthy Adults as determined by clinical judgment, including a medical history, physical exam and laboratory results, which confirms the absence of a current or past disease state considered significant by the investigator.
- Subjects have been informed properly regarding the study and signed the informed consent form.
- Subject will commit to comply with the instructions of the investigator and the schedule of the trial.
Inclusion Criteria for Children:
- Healthy Children as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.
- Parents/guardian(s) have been informed properly regarding the study and signed the informed consent form
- Parent/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.
Inclusion Criteria for Neonates:
- Neonate 0-5 days of age at the time of first dose, with cord blood available
- Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.
- The neonate was born full term (minimum of 36 completed weeks and maximum of 42 completed weeks gestation).
- Neonate birth weight 2500-4000 g inclusive.
- Parents or guardians have been informed properly regarding the study and signed the informed consent form
- Parents or guardians will commit to comply with the instructions of the investigator and the schedule of the trial
Exclusion Criteria for Adults:
- Subject concomitantly enrolled or scheduled to be enrolled in another trial
- Any direct relatives relationship with the study team.
- Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.
- Known history of allergy to any component of the vaccines
- Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy)
- Gastroenteritis in the 24 hours preceding enrollment.
- History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
- Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or corticosteroid therapy and other immunosuppresant).
- Subject consuming or expect to consume a probiotics within one week before and after vaccination
- Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
- Pregnancy & lactation (Adults).
- Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.
- Subject planning to move from the study area before the end of study period.
Exclusion Criteria for Children:
- Subject concomitantly enrolled or scheduled to be enrolled in another trial
- Any direct relatives relationship with the study team
- Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C ) within the 48 hours preceding enrollment
- Known history of allergy to any component of the vaccines
- Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy)
- Gastroenteritis in the 24 hours preceding enrollment.
- Any clinically significant history of chronic gastrointestinal disease including uncorrected congenital malformation of gastrointestinal tract that would predispose for Intusussception.
- History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
- Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or corticosteroid therapy and other immunosuppresant).
- Subjects consuming or expect to consume a probiotics within one week before and after vaccination.
- Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
- Individuals who have previously received any rotavirus vaccine.
- Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.
- Subject planning to move from the study area before the end of study period
Exclusion Criteria for Neonates:
- Subject concomitantly enrolled or scheduled to be enrolled in another trial.
- Any direct relatives relationship with the study team.
- Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.
- Subject with known or suspected history of allergy to any component of the vaccines.
- Subject with a biological mother with a known or suspected human immunodeficiency virus (HIV) infection.
- Subject with known or suspected major congenital malformations or genetically determined disease.
- Subject with intussusception.
- Subject with a known or suspected disease of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
- Subject with a known or suspected disease of the immune system or those who has received immunosuppresive therapy, including immunosuppresive courses of systemic corticosteroid.
- Subject who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product during the course of study.
- Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
- Subject immunized with non- EPI vaccines.
- Gastroenteritis in the 24 hours preceding enrollment.
- Subject planning to move from the study area before the end of study period.